Tacrolimus Exposure is Associated with Acute Rejection in the Early Phase After Kidney Transplantation: A Joint Modeling Approach
Open Access
- 25 July 2025
- journal article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 47 (6) , e82-e89
Abstract
Background: Reports regarding the relationship between tacrolimus exposure and the risk of acute kidney allograft rejection are conflicting. This may be explained by the previous use of methodological approaches that disregarded important factors in the analysis of longitudinal measurements and time-to-event data. Therefore, in this study, joint models were used to investigate the relationship between repeated measurements of tacrolimus predose concentrations (C 0 ) and time to acute biopsy-proven acute rejection (BPAR). Methods: This was a post hoc analysis of a randomized controlled trial in which living-donor kidney transplant recipients (KTR) received either a standard, bodyweight-based or CYP3A5 genotype-based tacrolimus starting dose. Joint modeling was performed by coupling a mixed-effects model for tacrolimus C 0 with a Cox proportional hazards model for the risk of rejection. Only the first episode of rejection was considered. Results: A total of 229 KTRs were included, of whom the incidence of BPAR was 10.5% (n = 24 KTRs) in the first 3 months posttransplant. A total of 3069 tacrolimus measurements were available for the analysis. A joint model adjusted for recipient age and peak panel reactive antibodies demonstrated that tacrolimus C 0 was associated with risk of rejection. A 1-unit increase in the time-normalized area under the curve for logarithmically (log)-transformed C 0 represented a change of −2.65 in the log of the relative hazard (95% credible interval: −5.05 to −0.36, P = 0.022). Conclusions: A negative association between the cumulative effect of tacrolimus C 0 and BPAR was observed using joint modeling. This demonstrated that KTRs with lower tacrolimus exposure were at a higher risk of rejection.Keywords
This publication has 46 references indexed in Scilit:
- Tacrolimus and Mycophenolic Acid Exposure Are Associated with Biopsy‐Proven Acute Rejection: A Study to Provide Evidence for Longer‐Term Target RangesClinical Pharmacology & Therapeutics, 2023
- Joint modeling of endpoints can be used to answer various research questions in randomized clinical trialsJournal of Clinical Epidemiology, 2022
- Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantationKidney International, 2014
- Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failureKidney International, 2014
- The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ TransplantationClinical Pharmacokinetics, 2013
- Importance of hematocrit for a tacrolimus target concentration strategyEuropean Journal of Clinical Pharmacology, 2013
- Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects modelsJournal of Clinical Epidemiology, 2012
- CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal RecipientsClinical Pharmacology & Therapeutics, 2007
- Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimusClinical Pharmacology & Therapeutics, 2003
- Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroidsBritish Journal of Clinical Pharmacology, 2003